TraderJoge

Trump and Netanyahu started this war. Now they must end it.

$LEXX pharma big boys going to come a knocking. *WATCH THIS VIDEO they just posted on LinkedIn. 📈 Their technology/platform is already proven in several $100B market sized disease states. This can do a $DRUG type move from dollar to $100. $CYCN was very nice today, but its going to fall off the map with only 1.5% of the merging company. Skyrocketed: $CYCN (▲ 311.61%):CYCN's stock surged after announcing a merger with Korsana Biosciences expected to close in Q3 2026. $ELAB (▲ 133.72%):ELAB signed a five-year agreement with Turbo-Jet, boosting market confidence and stock price significantly. $AGPU (▲ 119.75%):Axe Compute raised $343.5 million, enhancing AGPU's growth potential and financial stability.

the weight loss efficacy between both $NVO and $LLY oral pills are a few % and likely negligible in the real world. i think the differentiator comes down to having more flexibility in dosing as a way to deal with side effects and Lilly’s drug clearly wins on this. more doses per mg, and you can cut the pill in half without affecting absorption to allow for more tailored dosing. oral sema is limited by its snac so you can’t break it in half, and the jump from 9mg to 25mg is, ehh, a big one. people are gonna feel a wham of side effects on the highest dose and likely churn or switch to the injectable. either way, lilly wins here imo

GLP-1 pill war getting interesting… but this screams tolerability > everything. If patients drop off 14x more due to side effects, efficacy won’t matter—adherence drives real-world outcomes. No surprise 84% prefer Wegovy profile. This is shaping up as a usability + retention game, not just weight loss.

$LEXX add to the Bull case and most importantly 🚨 🐂 Lexaria is currently in an exclusive and extended MTA with a global Pharma company speculated to be $NVO or $LLY. Simultaneously they are having discussions with several other Pharma companies regarding the dehydraTECH platform. 🔥🔥🔥😮‍💨☝🏻🤝